

- Vollbracht C, Schneider B, Leendert V, Weiss G, **Auerbach L**, Beuth J
Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-
/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in
Germany.
In Vivo. 2011 Nov-Dec;25(6):983-90 **IF: 1,159**
- Kriegshäuser G, **Auner V, Schuster E, Holzer B**, Oberkanins C, Horvat R, **Speiser P, Zeillinger R**
KRAS mutation analysis in genomic DNA isolated from formalin-fixed paraffin-embedded ovarian
tissue: evaluation of a strip-based reverse-hybridisation assay.
J Clin Pathol. 2011;64:252-6 **IF: 2,475**
- Bodner K, Wierrani F, **Bodner-Adler B**
Maternal sepsis due to Clostridium perfringens after 2nd-trimester genetic amniocentesis.
J Obstet Gynecol. 2011 May;31(4):339-40 **IF: 0,440**
- Bodner K, Wierrani F, Grünberger W, **Bodner-Adler B**
Influence of the mode of delivery on maternal and neonatal outcomes:a comparison between elective
cesarean section and planned vaginal delivery in a low-risk obstetric population.
Arch Gynecol Obstet. 2011 Jun;283(6):1193-8 **IF: 1,072**
- Bodner K, **Bodner-Adler B**, Grünberger W
Evaluation of the contraceptive efficacy, compliance, and satisfaction with the transdermal
contraceptive patch system Evra: a comparison between adolescent and adult users.
Arch Gynecol Obstet. 2011 Mar;283(3):525-30 **IF: 1,072**
- Elenskaia K**, Haidvogel K, Heidinger C, **Doerfler D, Umek W, Hanzal E**
The greatest taboo: urinary incontinence as a source of shame and embarrassment.
Wien Klin Wochenschr. 2011 Oct;123(19-20):607-10 **IF: 0,747**
- Elenskaia K**, Thakar R, Sultan AH, Scheer I, Beggs A
The effect of pregnancy and childbirth on pelvic floor muscle function.
Int Urogynecol J. 2011 Nov;22(11):1421-7 **IF: 2,368**
- Brunner A, **Grimm C, Polterauer S, Hefler L**, Stani J, **Dudek G**, Horvat R
Expression of epidermal growth factor receptor and vascular endothelial growth factor in vaginal
squamous cell cancer.
Am J Obstet Gynecol. 2011 Feb;204(2):171.e1-6 **IF: 3,313**
- Brunner AH, **Grimm C, Polterauer S, Hefler L**, Stani J, Heinze G, Horvat R
The prognostic role of human papillomavirus in patients with vaginal cancer.
Int J Gynecol Cancer. 2011 Jul;21(5):923-9 **IF: 1,558**
- Grimm C**, Watrowski R, Baumühlner K, **Natter C, Tong D, Wolf A, Zeillinger R, Leodolter S,**
Reinhaller A, Hefler L
Genetic variations of interleukin-1 and -6 genes and risk of cervical intraepithelial neoplasia.
Gynecol Oncol. 2011 Mar 2;121:537-41 **IF: 3,760**
- Grimm C**, Watrowski R, **Polterauer S**, Baumühlner K, **Natter C, Rahhal J**, Heinze G, **Schuster E,**
Hefler L, Reinhaller A
Vascular Endothelial Growth Factor Gene Polymorphisms and Risk of Cervial Intraepithelial
Neoplasia.
Int J Gynecol Cancer. 2011 May;21(4):597-601 **IF: 1,558**

Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, **Grimm C**, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Dimitrios T, Novak Z, Peiretti M, Dunenova G, Macuks R, Hetland TE, Michelsen TM, Martins FC, Achimas-Cadariu P, Ulrikh EA, Uharcsek P, Malic S, Ognjenovic D, Zapardiel I, Johann S, Sukhin VS, Manchanda R
Gynecologic Oncology Training Systems in Europe: A Report from the European Network of Young Gynaecological Oncologists.
Int J Gynecol Cancer. 2011 Nov;21(8):1500-6 **IF: 1,558**

Gschwantler-Kaulich D, Riegler-Keil M, Ruecklinger E, **Singer CF**, **Seifert M**, Kubista E
Factors influencing the identification rate of the sentinel node in breast cancer.
Eur J Cancer Care. 2011 Sep;20(5):627-31 **IF: 1,138**

Gschwantler-Kaulich D, **Fink-Retter A**, Czerwenka K, Hudelist G, Kaulich A, Kubista E, **Singer CF**
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Tumour Biol. 2011 Jun;32(3):501-8 **IF: 2,026**

Fuereder T, Wanek T, Pflegerl P, **Jaeger-Lansky A**, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [¹⁸F]FLT uptake.
Clin Cancer Res. 2011 Aug 15;17(16):5322-32 **IF: 7,338**

Fuereder T, Hoeflmayer D, **Jaeger-Lansky A**, Rasin-Streden D, Strommer S, Fisker N, Hansen BJ, Crevenna R, Wacheck V
Sphingosine kinase 1 is a relevant molecular target in gastric cancer.
Anticancer Drugs. 2011 Mar;22(3):245-52 **IF: 2,376**

Brown DR, Garland SM, Ferris DG, **Joura E**, Steben M, James M, Radley D, Vuocolo S, Garner EI, Haupt RM, Bryan JT
The humoral response to Gardasil over four years as defined by Total IgG and competitive Luminex immunoassay.
Hum Vaccin. 2011;7:230-8 **IF: 2,042**

Ault KA, **Joura EA**, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Singhs HL, Harkins K, Rutkowski MA, Haupt RM, Garner EI; FUTURE I and II Study Group
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.
Int J Cancer. 2011;128:1344-5 **IF: 4,926**

Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, **Joura EA**, Djursing H, Sigurdsson K, Jefferson L, Alvarez F, Singhs HL, Lu S, James MK, Saah A, Haupt RM; FUTURE I, II and III Investigators
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.
Int J Cancer. 2011;128:1354-62 **IF: 4,926**

McCormack PL, **Joura EA**
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
BioDrugs. 2011;25:339-43 **IF: 4,192**

Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, **Joura EA**, Giacoletti KE, Radley DR, James MK, Saah AJ, Singhs HL; FUTURE I and II Investigators
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
Int J Cancer. 2011;129:2632-42 **IF: 4,926**

- Preyer O, Brugger PC, **Lami T, Hanzal E**, Prayer D, **Umek W**
High resolution magnetic resonance imaging of urethral anatomy in continent nulliparous pregnant women.
Eur J Radiol. 2011 Dec;80(3):736-9 **IF: 2,941**
- Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, **Leodolter S, Joura EA**, Ferris DG, Steben M, Hernandez-Avila M, Brown DR, Elbasha E, Munoz N, Paavonen J, Haupt RM; for the FUTURE I Investigators
Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance.
Cancer Epidemiol Biomarkers Prev. 2011;20:287-96 **IF: 3,919**
- Kristo I, Wilflingseder J, Kainz A, **Marschalek J**, Wekerle T, Mühlbacher F, Oberbauer R, Bodingbauer M
Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial.
Transpl Int. 2011 Sep;24(9):912-9 **IF: 3,211**
- Muin DA, Metka MM, Huber JC**
Menopause redefined by the shift of paradigms.
Climacteric. 2011;14(5):596 **IF: 1,938**
- Königsberg R, **Obermayr E**, Bises G, **Pfeiler G**, Gneist M, Wrba F, de Santis M, **Zeillinger R**, Hudec M, Dittrich C
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
Acta Oncol. 2011 Jun;50(5):700-10 **IF: 3,137**
- Ott J**, Promberger R, Kober F, Neuhold N, **Tea M, Huber JC**, Hermann M
Hashimoto's thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter.
Thyroid. 2011;21(2):161-7 **IF: 4,327**
- Ott J, Aust S**, Promberger R, **Huber JC, Kaufmann U**
Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals.
J Sex Med. 2011;8(8):2361-9 **IF: 3,957**
- Pfeiler G**, Glatz C, Königsberg R, Geisendorfer T, **Fink-Retter A**, Kubista E, **Singer CF, Seifert M**
Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
Climacteric. 2011 Jun;14(3):339-44 **IF: 1,938**
- Königsberg R, **Pfeiler G**, Kurzawa R, Hudec M, **Zeillinger R**, Dittrich C, **Singer C**
Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients.
Cancer Invest. 2011;29:180-6 **IF: 2,390**
- Pfeiler G**, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, **Singer CF**, Pöstlberger S, Steger GG, **Seifert M**, Dubsky P, Taucher S, Samonigg H, Bjelic-Radusic V, Greil R, Marth C, Gnant M
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
J Clin Oncol. 2011 Jul 1;29(19):2653-9 **IF: 18,970**
- Stickeler E, **Pils D**, Klar M, Orlowsk-Volk M, Zur Hausen A, Jäger M, Watermann D, Gitsch G, **Zeillinger R, Tempfer CB**
Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
Oncol Rep. 2011;26:1037-45 **IF: 1,686**

Wittinger M, Vanhara P, El-Gazzar A, Savarese-Brenner B, **Pils D**, Anees M, Grunt TW, Sibilia M, Holcman M, Horvat R, Schemper M, **Zeillinger R**, Schöfer C, Dolznig H, Horak P, Krainer M
hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer.
Clin Cancer Res. 2011 Dec 8;17(24):7816-27 **IF: 7,338**

Polterauer S, Grimm C, Zeillinger R, Heinze G, **Tempfer C, Reinthaller A, Hefler L**
Association of C-Reactive Protein (CRP) Gene Polymorphisms, Serum CRP Levels and Cervical
Cancer Prognosis.
Anticancer Res. 2011 Jun;31(6):2259-64 **IF: 1,656**

Polterauer S, Hofstetter G, **Grimm C, Rahhal J, Mailath-Pokorny M**, Kohl M, Concin N, **Tempfer C, Marth C, Reinthaller A**
Relevance of gamma-glutamyltransferase - a marker for apoptotic balance - in predicting tumor stage
and prognosis in cervical cancer.
Gynecol Oncol. 2011 Sep;122(3):590-4 **IF: 3,760**

Lee CK, Simes RJ, GebSKI V, Wollschlaeger K, Plante M, Vergote I, Mäenpää J, Ferrero A, Pisano C, Parma G, Berton-Rigaud D, Schröder W, Bentley J, **Reinthaller A**, Schmalfeldt B, Hirte H, Pfisterer J, Pujade-Lauraine E, Friedlander M on behalf of the Gynecologic Cancer Intergroup.
Development and validation of a nomogram to predict survival in CALYPSO AND AGO-2.5 patients
with platinum sensitive recurrent ovarian cancer.
Int J Gynecol Cancer. 2011 Volume 21, p S1-S1372, doi **IF: 1,558**

Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, **Reinthaller A**, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially
platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III
trial.
Ann Oncol. 2011 Oct 5, doi:10.1093/annonc/mdr441 **IF: 6,452**

Pötter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, Georg D, Schmid MP, **Reinthaller A**, Sturdza A, Kirisits C
Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D
conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.
Radiother Oncol. 2011 Jul;100(1):116-23 **IF: 4,337**

Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, **Reinthaller A**, Vergote I, Ferrandina G, Dell'Anna T, Huober J, Pujade-Lauraine E
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to
carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.
Gynecol Oncol. 2011 Aug;122(2):226-32 **IF: 3,760**

Harter P, Sehouli J, Reuss A, Hasenburger A, Scambia G, Cibula D, Mahner S, Vergote I, **Reinthaller A**, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the
Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study
Group, NOGGO, AGO-Austria, and MITO.
Int J Gynecol Cancer. 2011 Feb;21(2):289-95 **IF:1,558**

Schmid M, Kasprian G, **Marschalek J**, Posch A, Balassy C, Prayer D.
Maternal smoking and fetal lung volume-an in utero MRI investigation.
Prenat Diagn. 2011 May;31(5):491-5 **IF: 2,152**

Hofstetter G, Berger A, **Schuster E, Wolf A, Hager G**, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, **Speiser P**, Marth C, Zeimet AG, Ulmer H, **Zeillinger R**, Concin N
 $\Delta 133p53$ is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
Br J Cancer. 2011;105:1593-9 **IF: 4,831**

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, **Seifert M**, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Lancet Oncol. 2011 Jul;12(7):631-41

IF: 17,764

Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse TA, Birk Jensen U, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramón y Cajal T, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gómez Garcia EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, Kennedy MJ, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frénay M; CEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, **Singer CF, Tea MK, Pfeiler G, Dressler AC**, Hansen TO, Jønson L, Ejlersen B, Barkardottir RB, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Toland AE, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB; kConFab investigators, Neuhausen SL, Chun Ding Y, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; CIMBA.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Hum Mol Genet. 2011 Aug 15;20(16):3304-21

IF: 8,058

Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, **Singer CF, Pfeiler G**, Lynch HT, Garber JE, Couch F, Weitzel JN, Godwin A, Narod SA, Ganz PA, Daly MB, Isaacs C, Olopade OI, Tomlinson GE, Rubinstein WS, Tung N, Blum JL, Gillen DL

Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers.

Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1690-702

IF: 3,919

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (**Singer C – Collaborative Author**)

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Lancet. 2011 Nov 12;378(9804):1707-16

IF: 33,633

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (**Singer C – Collaborative Author**)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Lancet. 2011 Aug 27;378(9793):771-84

IF: 33,633

Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, **Singer CF**, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M; for the Austrian Breast and Colorectal Cancer Study Group.

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer.

Clin Cancer Res. 2011 Dec 15;17(24):7828-34

IF: 7,338

Wielscher M, Pulverer W, Peham J, Hofner M, Rappaport CF, **Singer C**, Jungbauer C, Nöhammer C, Weinhäusel A

Methyl-binding domain protein-based DNA isolation from human blood serum combines DNA analyses and serum-autoantibody testing.

BMC Clin Pathol. 2011 Sep 6;11:11

IF: 1,680

Filipits M, Rudas M, Jakesz R, Dubsy P, Fitzal F, **Singer CF**, Dietze O, Greil R, Jelen A, Sevela P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrman M, Gnant M; EP Investigators.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20

IF: 7,338

Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, **Singer CF**, Dressler AC, **Gschwantler-Kaulich D**, Blum JL, Tung N, Weitzel J, Lynch H, Garber J, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova OM, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame MA; GEMO Study Collaborators, Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MG, van Os TA, Wijnen J, Devilee P, Meijers-Heijboer HE, Blok MJ, Heikkinen T, Nevanlinna H, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang X, Thomassen M, Domchek S, Nathanson K, Caligo M, Jernström H, Liljegren A, Ehrencrona H, Karlsson P; SWE-BRCA, Ganz PA, Olopade OI, Tomlinson G, Neuhausen S, Antoniou AC, Chenevix-Trench G, Rebbeck TR. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1032-8.

IF: 3,919

Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, Janavicius R, Hansen TV, Nielsen FC, Ejlersen B, Osorio A, Munoz-Repeto I, Duran M, Godino J, Pertesi M, Benitez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Bonanni B, Viel A, Pasini B, Papi L, Ottini L, Savarese A, Bernard L, Radice P, Hamann U, Verheus M, Meijers-Heijboer HE, Wijnen J, Gomez Garcia EB, Nelen MR, Kets CM, Seynaeve C, Tilanus-Linthorst MM, van der Luijt RB, van Os T, Rookus M, Frost D, Jones JL, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Cook J, Donaldson A, Dorkins H, Gregory H, Eason J, Houghton C, Barwell J, Side LE, McCann E, Murray A, Peock S, Godwin A, Schmutzler RK, Rhiem K, Engel C, Meindl A, Ruehl I, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Kast K, Preisler-Adams S, Varon-Mateeva R, Schoenbuchner I, Fiebig B, Heinritz W, Schafer D, Gevensleben H, Caux-Moncoutier V, Fassy-Colcombet M, Cornelis F, Mazoyer S, Leone M, Boutry-Kryza N, Hardouin A, Berthet P, Muller D, Fricker JP, Mortemousque I, Pujol P, Coupier I, Lebrun M, Kientz C, Longy M, Sevenet N, Stoppa-Lyonnet D, Isaacs C, Caldes T, de Al Hoya M, Heikkinen T, Aittomaki K, Blanco I, Lazaro C, Barkardottir RB, Soucy P, Dumont M, Simard J, Montagna M, Tognazzo S, D'Andrea E, Fox S, Yan M, Rebbeck TR, Olopade OI, Weitzel JN, Lynch HT, Ganz PA, Tomlinson GE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet M, Bhatia J, Kauff N, **Singer CF**, **Tea MK**, **Gschwantler-Kaulich D**, **Fink-Retter A**, Mai PL, Greene MH, Imyanitov E, O'Malley FP, Ozcelik H, Glendon G, Toland AE, Gerdes AM, Thomassen M, Kruse TA, Birk Jensen U, Skytte AB, Caligo MA, Soller M, Henriksson K, von Wachenfeldt A, Arver B, Stenmark-Askmal M, Karlsson P, Ding YC, Neuhausen SL, Beattie M, Pharoah PD, Moysich KB, Nathanson KL, Karlan BY, Gross J, John EM, Daly MB, Buys SM, Southey MC, Hopper JL, Terry MB, Chung W, Miron AF, Goldgar D, Chenevix-Trench G, Easton DF, Andrulis IL, Antoniou AC, Family Registry BC, Embrace, Collaborators GS, Hebon, Network OC, Swe-Brca, Cimba.

Common breast cancer susceptibility alleles are associated with tumor subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.

Breast Cancer Res. 2011 Nov 2;13(6):R110

IF: 5,785

Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L, Verny-Pierre C, McGuffog L, Healey S, Szabo C, Greene MH, Mai PL, Andrulis IL; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Caligo MA, Friedman E, Laitman Y, Kaufman B, Aluch SS, Borg A, Karlsson P, Askmal MS, Bustinza GB; SWE-BRCA collaborators, Nathanson K, Domchek SM, Rebbeck TR, Benítez J, Hamann U, Rookus MA, van den Ouweland AM, Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gille HJ; HEBON; EMBRACE, Peock S, Frost D, Evans DG, Eeles R, Izatt L, Adlard J, Paterson J, Eason J, Godwin AK, Remon MA, Moncoutier V, Gauthier-Villars M, Lasset C, Giraud S, Hardouin A, Berthet P, Sobol H, Eisinger F, Paillerets BB, Caron O, Delnatte C; GEMO Study Collaborators, Oldgar D, Miron A, Ozcelik H, Buys S, Southey MC, Terry MB; the Breast Cancer Family Registry, **Singer CF**, Dressler AC, **Tea MK**, Hansen TV, Johannsson O, Piedmonte M, Rodriguez GC, Basil JB, Iank S, Toland AE, Montagna M, Isaacs C, Blanco I, Gayther SA, Moysich KB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Itsch N, Arnold N, Niederacher D, Sutter C, Gadzicki D, Fiebig B, Caldes T, Laframboise R, Nevanlinna H, Chen X, Beesley J, Spurdle AB, Neuhausen SL, Ding YC, Couch FJ, Wang X, Peterlongo P, Manoukian S, Bernard L, Radice P, Easton DF, Chenevix-Trench G, Antoniou AC, Stoppa-Lyonnet D, Mazoyer S, Sinilnikova OM; on behalf of the Consortium of Investigators of Modifiers of BRCA1/2.

Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.

Hum Mol Genet. 2011 Dec. 1;20(23):4732-47

IF: 8,058

Rebbeck TR, Mitra N, Domchek SM, Wan F, Klingner T, Tran TV, **Singer CF**, **Tea MK**, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Antoniou AC, Peock S, Evans DG, Paterson J, Kennedy JM, Donaldson A, Dorkins H, Easton DF, Rubinstein WS, Daly MB, Isaacs C, Nevanlinna H, Couch FJ, Andrulis IL, Friedman E, Laitman Y, Ganz PA, Tomlinson GE, Neuhausen SL, Narod SA, Helan CM, Greenberg R, Nathanson KL.

Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1 Interacting Genes.

Cancer Res. 2011 Sep. 1;71(17):5792-805

IF: 8,234

Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck TR, Jakubowska A, Lubinski J, Gronwald J, uzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Cajal TR, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van Os TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gómez Garcia EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Evans DG, Laloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, Kennedy MJ, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nagues C, Rouleau E, Pujol P, Coupier I, Fréney M; GEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Oldgar D; Breast Cancer Family Registry, **Singer CF**, **Tea MK**, Pfeiler G, Dressler AC, Hansen TO, Jønson L, Ejlersen B, Barkardottir RB, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Toland AE, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB; kConFab investigators, Neuhausen SL, Ding YC, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF, Chenevix-Trench G; on behalf of CIMBA.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Hum Mol Genet. 2011 Aug 15;20(16):3304-21

IF: 8,058

Im KM, Kirchhoff T, Wang X, Green T, Chow CY, Vijai J, Korn J, Gaudet MM, Fredericksen Z, Shane Pankratz V, Guiducci C, Crenshaw A, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Mai PL, Greene MH, Piedmonte M, Rubinstein WS; HEBON, Hogervorst FB, Rookus MA, Collée JM, Hoogerbrugge N, van Asperen CJ, Meijers-Heijboer HE, Van Roozendaal CE, Caldes T, Perez-Segura P, Jakubowska A, Lubinski J, Huzarski T, Blecharz P, Nevanlinna H, Aittomäki K, Lazaro C,

Blanco I, Barkardottir RB, Montagna M, D'Andrea E, kConFab, Devilee P, Olopade OI, Neuhausen SL, Peissel B, Bonanni B, Peterlongo P, **Singer CF**, Rennert G, Lejbkowitz F, Andrulis IL, Glendon G, Ozcelik H; Ontario Cancer Genetics Network, Toland AE, Caligo MA; SWE-BRCA, Beattie MS, Chan S; UKFOCR, Domchek SM, Nathanson KL, Rebbeck TR, Phelan C, Narod S, John EM, Hopper JL, Buys SS, Daly MB, Southey MC, Terry MB, Tung N, Hansen TV, Osorio A, Benitez J, Durán M, Weitzel JN, Garber J, Hamann U; EMBRACE, Peock S, Cook M, Oliver CT, Frost D, Platte R, Evans DG, Eeles R, Izatt L, Paterson J, Brewer C, Hodgson S, Morrison PJ, Porteous M, Walker L, Rogers MT, Side LE, Godwin AK, Schmutzler RK, Wappenschmidt B, Laitman Y, Meindl A, Deissler H, Varon-Mateeva R, Preisler-Adams S, Kast K, Venat-Bouvet L, Stoppa-Lyonnet D, Chenevix-Trench G, Easton DF, Klein RJ, Daly MJ, Friedman E, Dean M, Clark AG, Altshuler DM, Antoniou AC, Couch FJ, Offit K, Gold B.

Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Hum Genet. 2011 Nov;130(5):685-99

IF: 5,047

Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group (**Singer C – Collaborative Author**)

Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations.
Cancer. 2011 May 1;117(9):1812-8

IF: 5,131

Hudelist G, Ballard K, English J, Wright J, Banerjee S, Mastoroudes H, Thomas A, **Singer CF**, Keckstein J

Transvaginal sonography vs. clinical examination in the preoperative diagnosis of deep infiltrating endometriosis.

Ultrasound Obstet Gynecol. 2011 Apr;37(4):480-7

IF: 3,163

Brüner-Kubath C, Shabbir W, Saferding V, Wagner R, **Singer CF**, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

Breast Cancer Res Treat. 2011 Sep;129(2):387-400

IF: 4,859

Hudelist G, English J, Thomas AE, Tinelli A, **Singer CF**, Keckstein J

Diagnostic accuracy of transvaginal ultrasound for non-invasive diagnosis of bowel endometriosis: systematic review and meta-analysis.

Ultrasound Obstet Gynecol. 2011 Mar;37(3):257-63

IF: 3,163

Kubista B, Klinglmueller F, Bilban M, Pfeiffer M, Lass R, Giurea A, Funovics PT, Toma C, Dominkus M, Kotz R, Thalhammer T, Trieb K, Zettl T, **Singer CF**

Microarray analysis identifies distinct gene expression profiles associated with histological subtype in human osteosarcoma.

Int Orthop. 2011 Mar;35(3):401-11

IF: 1,561

Spurdle AB, Marquart L, McGuffog L, Healey S, Sinilnikova O, Wan F, Chen X, Beesley J, **Singer CF**, Dressler AC, **Gschwantler-Kaulich D**, Blum JL, Tung N, Weitzel J, Lynch H, Garber J, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Conroy D, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Selkirk CG, Daly M, Isaacs C, Stoppa-Lyonnet D, Sinilnikova OM, Buecher B, Belotti M, Mazoyer S, Barjhoux L, Verny-Pierre C, Lasset C, Dreyfus H, Pujol P, Collonge-Rame MA; GEMO Study Collaborators, Rookus MA, Verhoef S, Kriege M, Hoogerbrugge N, Ausems MG, van Os TA, Wijnen J, Devilee P, Meijers-Heijboer HE, Blok MJ, Heikkinen T, Nevanlinna H, Jakubowska A, Lubinski J, Huzarski T, Byrski T, Durocher F, Couch FJ, Lindor NM, Wang X, Thomassen M, Domchek S, Nathanson K, Caligo M, Jernström H, Liljegren A, Ehrencrona H, Karlsson P; SWE-BRCA, Ganz PA, Olopade OI, Tomlinson G, Neuhausen S, Antoniou AC, Chenevix-Trench G, Rebbeck TR.

Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1032-8

IF: 3,919

Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D; BCFR Investigators, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D; EMBRACE Investigators, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O; GEMO Study Collaborators, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M; HEBON Investigators, Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G; kConFab Investigators and the Consortium of Investigators of Modifiers of BRCA1/2, Kelemen LE, Kiemenev LA, Kjaer SK, Lambrechts D, Lapolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, **Singer CF**, Song H, Stram DO, Sutphen R, Lindblom A; SWE-BRCA Investigators, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA; Ovarian Cancer Association Consortium
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Clin Cancer Res. 2011 Jun 1;17(11):3742-50 **IF: 7,338**

Bates M, Sperinde J, Köstler WJ, Ali SM, Leitzel K, Fuchs EM, Paquet A, Lie Y, Sherwood T, Horvat R, **Singer CF**, Winslow J, Weidler JM, Huang W, Lipton A
Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
Ann Oncol. 2011 Sep;22(9):2014-20 **IF: 6,452**

Tea MK, Grimm C, Heinz-Peer G, Delancey J, **Singer C**
The predictive value of suspicious sonographic characteristics in atypical cyst-like breast lesions.
Breast. 2011 Apr;20(2):165-9 **IF: 2,089**

Tempfer CB, Wenzl R, Horvat R, **Grimm C, Polterauer S**, Buerkle B, **Reinhaller A, Huber JC**
Lymphatic spread of endometriosis to pelvic sentinel lymph nodes: a prospective clinical study.
Fertil Steril. 2011 Sep;96(3):692-6 **IF: 3,958**

Tomek K, Wagner R, Varga F, **Singer CF**, Karlic H, Grunt TW
Blockade of Fatty Acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Mol Cancer Res. 2011;9:1767-79 **IF: 4,373**

Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, **Tong D, Zeillinger R**, Thalhammer T, Jäger W
Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport.
Biomed Pharmacother. 2011;65:417-26 **IF: 2,208**

Walch K, Kowarik E, Leither K, Schätz T, **Dörfler D, Wenzl R**
Functional and anatomic results after creation of a neovagina according to Wharton-Sheares-George in patients with Mayer-Rokitansky-Küster-Hauser syndrome-long-term follow-up.
Fertil Steril 2011 Aug;96(2):492-497.e1 **IF: 3,958**

Bartel G, **Walch K**, Wahrmann M, **Pils S, Küssel L, Polterauer S, Tempfer C**, Böhmgig GA
Prevalence and qualitative properties of circulating anti-human leukocyte antigen alloantibodies after pregnancy: no association with unexplained recurrent miscarriage.
Hum Immunol. 2011 Feb;72(2):187-92 **IF: 2,872**

Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P
Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single center experience.
Int Arch Allergy Immunol. 2011;157:399-405 **IF: 2,235**

Valent P, Jäger E, Mitterbauer-Hohendanner G, Müllauer L, Schwarzinger I, Sperr W.R., Thalhammer R, **Wimazal F**

Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis.

Am J Cancer Res. 2011;1:531-41

IF: keiner

Witt A, Döner M, Petricevic L, Berger A, Germann P, Heinze G, Tempfer C

Antibiotic prophylaxis before surgery versus after cord clamping in elective cesarean delivery – a double-blind, prospective, randomized, placebo-controlled trial.

Arch Surg. 2011 Dec;146(12):1404-9

IF: 4,500

Yotova IY, Quan P, Leditznig N, Beer U, Wenzl R, Tschugguel W

Abnormal activation of Ras/ Raf/ MAPK and RhoA/ ROCKII signalling pathways in eutopic endometrial stromal cells of patients with endometriosis.

Hum Reprod. 2011 Apr;26(4):885-97

IF: 4,357

Hofstetter G, Berger A, Chamson M, Müller-Holzner E, Reimer D, Ulmer H, Uramoto H, Marth C, G Zeimet A, **Zeillinger R**, Concin N

Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.

Int J Gynecol Pathol. 2011;30:527-31

IF: 2,076

Olszewski U, Claffey J, Hogan M, Tacke M, **Zeillinger R**, Bednarski PJ, Hamilton G

Anticancer activity and mode of action of titanocene C.

Invest New Drugs. 2011;29:607-14

IF: 3,007

Van Zijl F, Mall S, Machat G, Pirker C, **Zeillinger R**, Weinhaeusel A, Bilban M, Berger W, Mikulits W

A human model of epithelial to mesenchymal transition to monitor drug efficacy in hepatocellular carcinoma progression.

Mol Cancer Ther. 2011;10:850-60

IF: 5,225

Bodner K, Laubichler P, Kimberger O, Czerwenka K, **Zeillinger R, Bodner-Adler B**

Expression of p16 protein and epidermal growth factor receptor in patients with adenocarcinoma of the uterine cervix: an immunohistochemical analysis.

Arch Gynecol Obstet. 2011 Mar;283(3):611-6

IF: 1,072

Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, **Zeillinger R**

Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept.

Cytometry B Clin Cytom. 2011;80:100-11

IF: 1,960

Kriegshäuser G, Fabjani G, Ziegler B, Zöchbauer-Müller S, End A, **Zeillinger R**

Biochip-based detection of KRAS mutation in non-small cell lung cancer.

Int J Mol Sci. 2011;12:8530-8

IF: 2,279